

ARIC Manuscript Proposal # 1449

PC Reviewed: 11/11/08
SC Reviewed: _____

Status: A
Status: _____

Priority: 2
Priority: _____

1.a. Full Title: Comparison of a novel equation for estimated glomerular filtration rate with a conventional one regarding the association with coronary heart disease, stroke, and all-cause mortality: The Atherosclerosis Risk in Communities (ARIC) Study

b. Abbreviated Title (Length 26 characters): CKD-EPI vs. MDRD formula & CVD

2. Writing Group:

Writing group members:

Kunihiro Matsushita, MD, PhD; Elizabeth Selvin, PhD, MPH; Lori D. Bash, MPH; Brad Astor, PhD, MPH; Josef Coresh, MD, PhD; others welcome.

I, the first author, confirm that all the coauthors have given their approval for this manuscript proposal. K. M. **[please confirm with your initials electronically or in writing]**

First author: Kunihiro Matsushita, MD, PhD
Address: Department of Epidemiology
Johns Hopkins Bloomberg School of Public Health
Welch Center for Prevention, Epidemiology, and Clinical Research
2024 E Monument Street, 2-600
Phone: (410)502-2051 Fax: (410)955-0476
E-mail: kmatsush@jhsph.edu

ARIC author to be contacted if there are questions about the manuscript and the first author does not respond or cannot be located (this must be an ARIC investigator).

Name: Elizabeth Selvin PhD, MPH
Address: Department of Epidemiology
Johns Hopkins Bloomberg School of Public Health
Welch Center for Prevention, Epidemiology, and Clinical Research
2024 E Monument Street, 2-600
Phone: (410) 614-3752 Fax: (410)955-0476
E-mail: lselvin@jhsph.edu

3. Timeline:

Data to be used in this proposal are already available. Analyses and manuscript preparation will be performed over the next 6 months.

4. Rationale:

Numerous articles have reported that reduced glomerular filtration rate (GFR) is a predictor of incident cardiovascular disease (CVD) [1-14]. Consequently, individuals with impaired GFR, even at moderate levels, are placed in the highest risk group for CVD in clinical guidelines [15,16].

Currently, the Modification of Diet in Renal Disease (MDRD) equation is the conventional formula used in clinical practice to estimate GFR. However, the MDRD formula has been shown to be relatively imprecise in individuals with GFR higher than 60 ml/min/1.73m² [5], potentially resulting in misclassification of risk for future cardiovascular events.

The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) group soon will publish a novel equation designed to improve the estimation of GFR, particularly among individuals with normal or mildly impaired kidney function. However, it is unknown whether a classification based on this novel CKD-EPI equation is more strongly associated with future CVD events than the MDRD equation.

Therefore, the objective of this study is to compare the CKD-EPI and the MDRD equation regarding their associations with CVD and all-cause mortality in the ARIC Study.

5. Main Hypothesis/Study Questions:

Hypothesis: The classification of kidney function according to the CKD-EPI equation will be more strongly associated with incident CVD and all-cause mortality than the same categorization scheme using the MDRD equation.

6. Design and analysis (study design, inclusion/exclusion, outcome and other variables of interest with specific reference to the time of their collection, summary of data analysis, and any anticipated methodologic limitations or challenges if present).

Inclusions:

All black and white ARIC subjects with measured serum creatinine, and other variables (age, sex) required for the estimation of GFR.

Exclusions:

Ethnicity other than black or white

Individuals missing data required to estimate GFR

Exposure: GFR estimated by the CKD-EPI and the MDRD equations

Kidney function will be estimated using both the CKD-EPI and the simplified version of MDRD equation incorporating data of serum creatinine concentration, age, gender, and race from visit 1 and measured in ml/min/1.73m².

Outcome:

Incident coronary heart disease (CHD) including a hospitalized myocardial infarction, fatal CHD, or cardiac procedures, stroke, and all-cause death through 2004

Covariates:

Sociodemographics: age, race, gender, education

Physical information: blood pressure, body mass index

Lifestyle: smoking status and alcohol habit

Comorbidities: hypertension, diabetes, dyslipidemia, history of CVD

Statistical Analysis Plan:

First, we will compute incidence rates for CVD and all-cause mortality among clinical categories of GFR 1) <30, 2) 30 to 59, 3) 60 to 89, 4) ≥ 90 ml/min/1.73m² calculated based on both equations and compare their trends.

Then, we will compare the equations across above clinical categories of GFR, classifying participants using a 4*4 table according to these categories. We will compare incidence rates of CVD and all-cause death in the different CKD-EPI GFR groups among a given MDRD GFR stratum and vice versa. Through this analysis, we will be able to identify the proportion of individuals reclassified by the CKD-EPI equation compared to the MDRD equation. Moreover, we will calculate the net reclassification index (NRI) proposed by Pencina MJ, et al. [17] as a measure of relevant change in these clinical categories [18]. The NRI is the difference in proportions moving up and down among individuals with and without outcomes and allows us to estimate the statistical significance about clinical relevance of observed reclassification [18].

We will conduct subgroup analyses stratifying subjects according to race and gender, since dissimilar indices used for race and gender in the equations may affect the results.

Limitations:

Of the ARIC participants, only 3% had GFR less than 60 ml/min/1.73m² at visit 1. So, statistical power to detect any difference between the two equations in this group with low kidney function will be limited. However, since CKD-EPI equation was initiated aiming at better estimation of GFR above 60, results obtained by this cohort are particularly important.

Also, the CKD-EPI equation was compared to the MDRD equation but not a “gold standard” measurement of GFR. However, measurement of GFR is considered cumbersome and expensive and is not usually performed in routine clinical practice or population-based research, and, thus, the MDRD equation conventionally has been used to estimate GFR in those circumstances [19]. Therefore, these data reflect a realistic clinical scenario.

7.a. Will the data be used for non-CVD analysis in this manuscript? ☐ Yes
☒ No

b. If Yes, is the author aware that the file ICTDER03 must be used to exclude persons with a value RES_OTH = “CVD Research” for non-DNA analysis, and for DNA analysis RES_DNA = “CVD Research” would be used? ☐ Yes
☐ No

(This file ICTDER03 has been distributed to ARIC PIs, and contains the responses to consent updates related to stored sample use for research.)

8.a. Will the DNA data be used in this manuscript? ☐ Yes ☒ No

8.b. If yes, is the author aware that either DNA data distributed by the Coordinating Center must be used, or the file ICTDER03 must be used to exclude those with value RES_DNA = “No use/storage DNA”?
☐ Yes ☐ No

8.c. If yes, is the author aware that the participants with RES_DNA = 'not for profit' restriction must be excluded if the data are used by a for profit group?
____ Yes ____ No

9. The lead author of this manuscript proposal has reviewed the list of existing ARIC Study manuscript proposals and has found no overlap between this proposal and previously approved manuscript proposals either published or still in active status. ARIC Investigators have access to the publications lists under the Study Members Area of the web site at: <http://www.csc.unc.edu/ARIC/search.php>

___X___ Yes _____ No

10. What are the most related manuscript proposals in ARIC (authors are encouraged to contact lead authors of these proposals for comments on the new proposal or collaboration)?

#172: Levels of Albumin, Creatinine, and Incident Coronary Heart Disease; Heiss, G

#758: Serum creatinine and risk of CVD: Atherosclerosis Risk in Communities (ARIC) Study; Ibrahim H

#952: Kidney function and anemia as risk factors for coronary heart disease and mortality: The ARIC Study; Astor, BC

#1028: Cardiovascular risk among adults with chronic kidney disease, with or without prior myocardial infarction; Wattanakit, K

#1058: Kidney Function and Risk of Peripheral Arterial Disease: Results from the Atherosclerosis Risk in Communities (ARIC) Study; Wattanakit, K

#1118: Reduced Kidney Function as a risk factor for incident heart failure: The ARIC Study; Kottgen, A

#1244: Kidney Dysfunction and Sudden Cardiac Death among Participants in the ARIC Study; Deo, R

#1348: Chronic kidney disease and risk of hospitalization: The Atherosclerosis Risk in Communities Study; Bash, LD

11. a. Is this manuscript proposal associated with any ARIC ancillary studies or use any ancillary study data? ____ Yes __X__ No

11.b. If yes, is the proposal

___ **A. primarily the result of an ancillary study (list number* _____)**

___ **B. primarily based on ARIC data with ancillary data playing a minor role (usually control variables; list number(s)* _____)**

*ancillary studies are listed by number at <http://www.csc.unc.edu/aric/forms/>

12. Manuscript preparation is expected to be completed in one to three years. If a manuscript is not submitted for ARIC review at the end of the 3-years from the date of the approval, the manuscript proposal will expire.

References

1. Kottgen A, Russell SD, Loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, Chambless LE, Coresh J. Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. *J Am Soc Nephrol.* 2007 ;18:1307-1315.
2. Astor BC, Coresh J, Heiss G, Pettitt D, Sarnak MJ. Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. *Am Heart J.* 2006;151:492-500.
3. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, Coresh J, Levey AS, Sarnak MJ. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. *J Am Coll Cardiol.* 2003;41:47-55.
4. Manjunath G, Tighiouart H, Coresh J, Macleod B, Salem DN, Griffith JL, Levey AS, Sarnak MJ. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. *Kidney Int.* 2003;63:1121-1129.
5. Wattanakit K, Folsom AR, Selvin E, Coresh J, Hirsch AT, Weatherley BD. Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk in Communities (ARIC) Study. *J Am Soc Nephrol.* 2007;18:629-636.
6. Weiner DE, Tabatabai S, Tighiouart H, Elsayed E, Bansal N, Griffith J, Salem DN, Levey AS, Sarnak MJ. Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. *Am J Kidney Dis.* 2006;48:392-401.
7. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. *J Am Soc Nephrol.* 2004;15:1307-1315.
8. Abramson JL, Jurkowitz CT, Vaccarino V, Weintraub WS, McClellan W. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. *Kidney Int.* 2003;64:610-615.
9. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. *Ann Intern Med.* 2001;134:629-636.
10. Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, Berger PB. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. *J Am Coll Cardiol.* 2002;39:1113-1119.
11. Fried LF, Shlipak MG, Crump C, Bleyer AJ, Gottdiener JS, Kronmal RA, Kuller LH, Newman AB. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. *J Am Coll Cardiol.* 2003;41:1364-1372.
12. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. *J Am Coll Cardiol.* 2000;35:681-689.
13. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med.* 2004;351:1296-1305.
14. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD,

- Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. *N Engl J Med*. 2004;351:1285-1295.
15. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis*. 2002;39(Suppl 1):S1-266.
 16. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. *Circulation*. 2003;108:2154-2169.
 17. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. *Stat Med*. 2008;27:157-172.
 18. Cook NR. Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. *Clin Chem*. 2008;54:17-23.
 19. Vassalotti JA, Stevens LA, Levey AS. Testing for chronic kidney disease: a position statement from the National Kidney Foundation. *Am J Kidney Dis*. 2007;50:169-180.